Dr. Hahn Discusses Abiraterone Versus Docetaxel in Prostate Cancer
Andy Hahn, MD
Andy Hahn, MD, resident, University of Utah School of Medicine, discusses abiraterone acetate (Zytiga) versus docetaxel in the treatment of patients with prostate cancer.
Although there has not yet been a head-to-head trial comparing androgen deprivation therapy (ADT) plus abiraterone versus ADT plus docetaxel, STAMPEDE reported out data with these 2 combinations simultaneously. Data from this trial showed that when comparing abiraterone with docetaxel, there was no significant difference in overall survival or metastasis-free survival. There was a trend in favor of abiraterone regarding progression-free survival and failure-free survival, but these were surrogate endpoints, Hahn says.
The PEACE-1 trial, which will read out in the next few years, may offer an answer to the question of abiraterone versus docetaxel, Hahn says. This trial is evaluating a variety of combinations, including a head-to-head comparison of ADT plus docetaxel versus ADT plus abiraterone.